JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SOMANI, P.
Right arrow Articles by LADDU, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SOMANI, P.
Right arrow Articles by LADDU, A. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETANILIDE
Journal of Pharmacology And Experimental Therapeutics, Vol. 170, Issue 1, 72-78, 1969
Copyright © 1969 by American Society for Pharmacology and Experimental Therapeutics


BLOCKADE OF CARDIAC EFFECTS OF ISOPROTERENOL BY 4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)-ACETANILIDE (ICI 50,172)

PITAMBAR SOMANI 1 and ATUL R. LADDU 1

1 Department of Pharmacology, Marquette School of Medicine, Milwaukee, Wisconsin

The beta adrenergic blocking activity of 4-(2-hydroxy-3-isopropyl-aminopropoxy)-acetanilide (ICI 50,172) was investigated in the isolated turtle heart preparation and the blood-perfused supported dog heart preparation (ISHP). The pA2 value for ICI 50,172 in the turtle heart was found to be 7.0. Intracoronary administration of isoproterenol produced a dose-dependent increase in heart rate, left ventricular contractile force, left ventricular systolic pressure and myocardial oxygen consumption and a decrease in coronary artery perfusion pressure in the ISHP. Pretreatment with 0.25 mg/kg of ICI 50,172 effectively blocked the myocardial effects of isoproterenol in a competitive manner. ICI 50,172 reduced the myocardial oxygen consumption of the ISHP with little or no effect on myocardial contractility or heart rate, suggesting an improved myocardial efficiency.

Submitted on March 10, 1969
Accepted on August 1, 1969







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics.